Insider Trading June 5, 2026 05:01 PM

nCino Executive Officer Executes Pre-Arranged Share Sale

CEO and President Sean Desmond Offloads $131,120 Worth of Stock Under Rule 10b5-1 Plan

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
NCNO

nCino, Inc. (NASDAQ: NCNO) CEO and President Sean Desmond completed a transaction involving the sale of 8,064 common shares on June 3, 2026. The transaction, valued at $131,120, was executed at a price of $16.26 per share. This sale was conducted under a Rule 10b5-1 trading plan that Desmond established on January 6, 2026. Prior to the sale, Desmond exercised an equal number of stock options, acquiring 8,064 shares at an exercise price of $4.98 per share, totaling $40,158. Following the transaction, Desmond holds 1,262,492 shares of nCino common stock directly and 196,420 derivative shares in the form of stock options. Analysts from InvestingPro suggest that nCino may be undervalued, with a consensus buy rating and projected upside potential. The company recently reported its first-quarter fiscal 2027 results, showing revenue growth but falling short of earnings expectations.

nCino Executive Officer Executes Pre-Arranged Share Sale
NCNO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • nCino CEO and President Sean Desmond sold 8,064 shares for $131,120 under a Rule 10b5-1 plan.
  • The company reported first-quarter fiscal 2027 revenue of $159.4 million, exceeding estimates by $3.6 million.
  • nCino's EPS missed expectations by 55.93%, reported at $0.12 versus the forecasted $0.2723.

Sean Desmond, who serves as both CEO and President of nCino, Inc. (NASDAQ: NCNO), executed a sale of 8,064 shares of the company's common stock on June 3, 2026. The total value of the transaction reached $131,120, with the shares sold at a price of $16.26 each. This transaction was facilitated under a Rule 10b5-1 trading plan, which Mr. Desmond originally adopted on January 6, 2026.

Before executing the sale, Mr. Desmond acquired an equivalent number of common stock shares, totaling 8,064, by exercising stock options. These options were exercisable at the time and carried an exercise price of $4.98 per share, resulting in a total cost of $40,158. This acquisition was also part of the same Rule 10b5-1 trading plan.

Following these transactions, Mr. Desmond directly holds 1,262,492 shares of nCino common stock. He also holds 196,420 derivative shares in the form of stock options. According to InvestingPro analysis, nCino appears undervalued at current levels, with analysts maintaining a buy rating and projecting significant upside potential. The platform offers 13 additional ProTips for NCNO investors seeking deeper insights.

In other recent news, nCino Inc. announced its first-quarter fiscal 2027 results, highlighting a significant revenue performance. The company reported revenue of $159.4 million, surpassing the consensus estimate of $155.8 million and marking an 11% year-over-year increase. Despite this positive revenue growth, nCino's earnings per share (EPS) fell short of expectations, with actual EPS reported at $0.12 compared to the forecasted $0.2723, resulting in a 55.93% miss.

Citizens maintained a Market Outperform rating for nCino, with a price target of $23.00, following these financial results. The revenue growth was noted as a positive aspect, showing an improvement from the 6% growth in the previous quarter. However, the significant miss in EPS overshadowed this revenue achievement, reflecting investor concerns. The stock's performance in aftermarket trading indicated the market's reaction to the earnings miss. These developments provide a snapshot of nCino's financial health and market perception in the recent period.

Risks

  • The significant miss in EPS may lead to increased investor scrutiny and potential market volatility.
  • The company's ability to maintain its Market Outperform rating and $23.00 price target may be challenged by future earnings performance.
  • The aftermarket trading reaction suggests ongoing market uncertainty regarding nCino's financial health.

More from Insider Trading

Nano Nuclear Energy Director Disposes of All Shares Following RSU Vesting Jun 5, 2026 Beta Bionics Director Jones Christy Executes Pre-Arranged Stock Sale Jun 5, 2026 MiNK Therapeutics Director Disposes of $19,141 in Common Stock Jun 5, 2026 Beta Bionics Executive Sells Shares Under Pre-Arranged Plan Jun 5, 2026 Outset Medical CFO Executes Tax-Related Stock Sale Amid Strategic Focus Jun 5, 2026